Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2019-11-12 Financial Supplement Da…
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Press Release
Financial Supplement Data Classification · 60% confidence The document is very short (350 characters) and contains only a brief table of segment revenues for Q2 FY20 without any narrative, analysis, or detailed financial statements. There is no indication that this is a full financial report or an earnings release with key highlights. It appears to be a snippet of financial data, likely supplementary or part of a larger report. Given the brevity and lack of context, it does not qualify as an Interim/Quarterly Report (IR) or Earnings Release (ER). It is more consistent with a Financial Supplement Data (XLSX) or a Fund Information/Factsheet (FS) type, but since it is a small table of segment revenues, the best fit is Financial Supplement Data (XLSX). Confidence is moderate due to limited content.
2019-11-12 English
Dividend
Regulatory Filings
2019-11-12 English
Un-audited Financial Results for the quarter and half year ended 30th September, 2019
Regulatory Filings
2019-11-12 English
Press Release
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 191 characters, which is very short and contains no report content. It appears to be a placeholder or an announcement without actual report data. According to the MENU VS MEAL RULE, such a short document with no report content is likely a Report Publication Announcement or a Regulatory Filing. Given the lack of any indication of report attachment or publication notice, and no other context, the safest classification is Regulatory Filings (RNS) as a fallback category.
2019-11-11 English
NATCO's 1st key product in Crop Health Sciences for India- Chlorantraniliprole
Regulatory Filings
2019-11-11 English
Earning call for Q2 and half year ended FY20 at 11.00 a.m. IST on November 13, 2019
Regulatory Filings
2019-11-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.